Skyrizi Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to increasing diagnosis of autoimmune disorders, limitations of conventional immunosuppressive therapies, rising adoption of biologics in dermatology and gastroenterology, expansion of specialty care access, growing clinical trial success rates.

The growth in the forecast period can be attributed to increasing expansion into new inflammatory indications, rising investments in next-generation biologics, growing patient preference for convenient dosing regimens, increasing healthcare focus on durable remission, expansion of biologic treatment guidelines. Major trends in the forecast period include increasing adoption of il-23 targeted therapies, rising use across multiple autoimmune indications, growing preference for long-dosing interval biologics, expansion of self-administered injectable formats, enhanced focus on long-term disease control.

The growing interest in personalized medicine is expected to drive the growth of the Skyrizi market in the future. Personalized medicine tailors treatment and healthcare strategies to the unique characteristics of each patient, including their genetic makeup, environment, and lifestyle, to achieve the most effective and precise outcomes. The rising interest in personalized medicine is fueled by advancements in genomic technologies, a deeper understanding of molecular biology, the increasing availability of precision diagnostic tools, and the demand for targeted therapies that improve patient outcomes while minimizing side effects. Skyrizi supports personalized medicine by offering a targeted biologic therapy that specifically inhibits interleukin-23 (IL-23), allowing healthcare providers to tailor treatments for patients with moderate to severe autoimmune diseases, such as psoriasis and ulcerative colitis, based on individual responses and disease characteristics. This improves efficacy and minimizes treatment-related side effects. For example, in February 2024, the Personalized Medicine Coalition, a U.S.-based healthcare organization, reported that in 2023, the FDA approved 16 new personalized treatments for rare disease patients, up from six in 2022. Therefore, the growing interest in personalized medicine is expected to drive the Skyrizi market forward.

Major companies in the Skyrizi market are focusing on developing innovative solutions, such as interleukin-23 (IL-23) inhibitor therapies, to meet the increasing demand for targeted, highly effective treatments for autoimmune and chronic inflammatory diseases. IL-23 inhibitors work by selectively blocking the p19 subunit of the IL-23 cytokine, which plays a central role in driving inflammatory pathways. This targeted approach offers improved efficacy and safety compared to traditional broad-spectrum immunosuppressants. For instance, in July 2024, AbbVie Inc., a U.S.-based biopharmaceutical company, received European Commission approval for Skyrizi (risankizumab) to treat adults with moderately to severely active ulcerative colitis who have not responded to or are intolerant to conventional or biologic therapies. Skyrizi is a monoclonal antibody that selectively inhibits IL-23, helping reduce inflammation and promote mucosal healing. Clinical evidence from the Phase 3 INSPIRE and COMMAND trials showed strong outcomes, including significant mucosal healing and sustained remission, especially in patients without prior biologic or JAK inhibitor use.

In March 2023, AbbVie partnered with Boehringer Ingelheim to develop and commercialize immunology therapies. This collaboration allows AbbVie to leverage Boehringer Ingelheim's early discoveries in IL-23 biology while expanding Skyrizi’s global market reach and label indications. Boehringer Ingelheim is a Germany-based provider of research-driven pharmaceuticals and biologics, particularly in immunology and inflammation.

Major companies operating in the skyrizi market are AbbVie Inc.

North America was the largest region in the skyrizi market in 2025. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the skyrizi market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the skyrizi market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are impacting the skyrizi market by increasing costs of imported biologic raw materials, formulation components, pre-filled syringe devices, and specialized manufacturing equipment. North America and Europe experience the most impact due to cross-border biologics supply dependencies, while Asia-Pacific faces increased export and compliance costs. These tariffs are contributing to higher treatment costs and supply chain complexity for biologic therapies. However, they are also accelerating regional biologics manufacturing investments, localized packaging operations, and long-term supply chain diversification strategies.

The skyrizi market research report is one of a series of new reports that provides skyrizi market statistics, including skyrizi industry global market size, regional shares, competitors with a skyrizi market share, detailed skyrizi market segments, market trends and opportunities, and any further data you may need to thrive in the skyrizi industry. This skyrizi market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Skyrizi is a prescription medication used to treat certain autoimmune conditions, including moderate to severe plaque psoriasis, active psoriatic arthritis, and Crohn's disease, by reducing inflammation in the body. The mechanism of action of Skyrizi (risankizumab-rzaa) involves selectively targeting and inhibiting interleukin-23 (IL-23), a protein that plays a key role in inflammatory and immune responses.

The main indications for Skyrizi include plaque psoriasis, Crohn's disease, and ulcerative colitis. Plaque psoriasis is a common form of psoriasis characterized by raised, red patches covered with silvery-white scales. It typically appears on the scalp, elbows, and knees, causing discomfort and irritation. Skyrizi is available in various formulations, including pre-filled syringes and vials, and is distributed through multiple channels such as hospital pharmacies, retail pharmacies, and online pharmacies.

The skyrizi market consists of sales of intravenous (IV) infusion for induction and subcutaneous (SC) injection and pen injectors. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.